PDF(Pubmed)
Abstract：
UNASSIGNED: The aim of this study was to observe the remission of primary membranous nephropathy (PMN) and evaluate the efficacy of tacrolimus (TAC) monotherapy for PMN in comparison with TAC combined with a low-dose glucocorticoid (GC) protocol (TAC + GC).
UNASSIGNED: This was tested in a prospective monocentric observational trial of 70 patients with PMN, of whom 34 received TAC (0.05-0.075 mg/kg/day) or 36 received TAC (0.05-0.075 mg/kg/day) and GC (0.3-0.5 mg/kg/day of prednisone).
UNASSIGNED: At 3, 6, 9, and 12 months of treatment, the effective rates in the TAC group and the TAC + GC group were similar (P > 0.05). The urinary protein quantification was reduced in patients under both therapeutic protocols, and the differences in the proteinuria quantification at 3, 6, 9, and 12 months of treatment were not statistically significant between the two groups (P > 0.05). The overall incidence of adverse reactions in the TAC group was lower than that in the TAC + GC group (23.5% < 36.1%), and the difference was statistically significant (P < 0.05).
UNASSIGNED: TAC monotherapy for PMN could effectively reduce urinary protein quantification and increase serum albumin levels. Compared with TAC + GC, TAC monotherapy for PMN had no difference in efficacy and fewer incidences of adverse reactions.
UNASSIGNED: This was tested in a prospective monocentric observational trial of 70 patients with PMN, of whom 34 received TAC (0.05-0.075 mg/kg/day) or 36 received TAC (0.05-0.075 mg/kg/day) and GC (0.3-0.5 mg/kg/day of prednisone).
UNASSIGNED: At 3, 6, 9, and 12 months of treatment, the effective rates in the TAC group and the TAC + GC group were similar (P > 0.05). The urinary protein quantification was reduced in patients under both therapeutic protocols, and the differences in the proteinuria quantification at 3, 6, 9, and 12 months of treatment were not statistically significant between the two groups (P > 0.05). The overall incidence of adverse reactions in the TAC group was lower than that in the TAC + GC group (23.5% < 36.1%), and the difference was statistically significant (P < 0.05).
UNASSIGNED: TAC monotherapy for PMN could effectively reduce urinary protein quantification and increase serum albumin levels. Compared with TAC + GC, TAC monotherapy for PMN had no difference in efficacy and fewer incidences of adverse reactions.
摘要：
■本研究的目的是观察原发性膜性肾病（PMN）的缓解情况，并与TAC联合低剂量糖皮质激素（GC）方案（TACGC）相比，评估他克莫司（TAC）单药治疗PMN的疗效。
■这是在一项对70名PMN患者进行的前瞻性单中心观察试验中进行的。其中34人接受TAC（0.05-0.075mg/kg/天）或36人接受TAC（0.05-0.075mg/kg/天）和GC（泼尼松0.3-0.5mg/kg/天）。
■在治疗3、6、9和12个月时，TAC组与TAC+GC组有效率相似(P>0.05)。在两种治疗方案下，患者的尿蛋白定量均降低，两组治疗3、6、9、12个月的蛋白尿定量差异无统计学意义(P>0.05)。TAC组不良反应总发生率低于TAC+GC组(23.5%<36.1%),差异有统计学意义(P<0.05)。
■TAC单药治疗PMN可有效降低尿蛋白定量，提高血清白蛋白水平。与TAC+GC相比，TAC单药治疗PMN的疗效无差异，不良反应发生率较低。
■这是在一项对70名PMN患者进行的前瞻性单中心观察试验中进行的。其中34人接受TAC（0.05-0.075mg/kg/天）或36人接受TAC（0.05-0.075mg/kg/天）和GC（泼尼松0.3-0.5mg/kg/天）。
■在治疗3、6、9和12个月时，TAC组与TAC+GC组有效率相似(P>0.05)。在两种治疗方案下，患者的尿蛋白定量均降低，两组治疗3、6、9、12个月的蛋白尿定量差异无统计学意义(P>0.05)。TAC组不良反应总发生率低于TAC+GC组(23.5%<36.1%),差异有统计学意义(P<0.05)。
■TAC单药治疗PMN可有效降低尿蛋白定量，提高血清白蛋白水平。与TAC+GC相比，TAC单药治疗PMN的疗效无差异，不良反应发生率较低。
